---
title: "Gyre Therapeutics to present CG923308 data; expects IND submission Q1 2027"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286472408.md"
description: "Gyre Therapeutics will present preclinical data on CG923308 at a Shanghai conference, highlighting its potent anti-tumor activity and oral bioavailability. The company aims to leverage its collaboration with Cullgen for accelerated development and anticipates submitting an IND for CG923308 in Q1 2027. The presentation includes a detailed slide deck on their pipeline and strategy."
datetime: "2026-05-14T21:33:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286472408.md)
  - [en](https://longbridge.com/en/news/286472408.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286472408.md)
---

# Gyre Therapeutics to present CG923308 data; expects IND submission Q1 2027

**Gyre Therapeutics will present preclinical and translational data on CG923308 and its China-enabled integrated pipeline at a Shanghai scientific conference.**

**Key Highlights:**

-   Gyre is presenting an Exhibit 99.1 slide deck at a Shanghai conference describing pipeline, strategy and CG923308 data.
-   CG923308 is a CDK2–cyclin E degrader showing potent, selective degradation and anti-tumor activity in multiple preclinical models.
-   Preclinical data show oral bioavailability across species, tumor growth inhibition, senescence induction and tolerability in CDX/PDX models.
-   Combined Gyre–Cullgen strategy leverages China discovery, manufacturing and commercialization to accelerate degrader and DAC programs.
-   Cullgen anticipates submitting an IND for CG923308 in Q1 2027 (as stated in the presentation).

Original SEC Filing: GYRE THERAPEUTICS, INC. \[ GYRE \] - 8-K - May. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [GYRE.US](https://longbridge.com/en/quote/GYRE.US.md)

## Related News & Research

- [Gyre Therapeutics Q1 revenue rises 2% but misses analyst estimates](https://longbridge.com/en/news/285527827.md)
- [Gen Z's AI backlash is getting louder](https://longbridge.com/en/news/286922566.md)
- [BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models](https://longbridge.com/en/news/286973840.md)
- [Did Nurix’s (NRIX) EHA Oral BTK Degrader Data Just Reframe Its Oncology Investment Narrative?](https://longbridge.com/en/news/286475954.md)
- [Nvidia’s AI Lead Is Back in Focus as Wolfe Research Doubles Down](https://longbridge.com/en/news/286680544.md)